You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
据报阿斯利康跳过紧急使用许可 寻求FDA批准新冠疫苗全面销售许可
阿思达克 05-10 10:08
《华尔街日报》报道,阿斯利康(AZN.US)可能不会向美国食品及药物管理局(FDA)申请新冠疫苗的紧急使用授权,而是申请耗时较长的全面销售许可,意味着将推迟在美国推出疫苗。

阿斯利康未有直接回应报道,仅称会继续推进向FDA提交申请,除会提交美国的试验数据外,亦会呈上至今为止所有研究分析与药物安全监测,以及真实疫苗数据。

上周阿斯利康表示,正在尽快收集疫苗数据以在美国申请许可,预计在未来数周内获得批准。而白宫亦在4月下旬表示,美国将在未来数周内开始与其他国家分享多达6,000万剂的阿斯利康疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account